Tourmaline Bio Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Tourmaline. In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read more at globenewswire.com